Clinical trial
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in…
NCT00417118 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00417118 |
|---|---|
| Title | An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder |
| Official title | An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, With Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Patients With Generalized Anxiety Disorder |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Anxiety |
| Intervention type | Drug |
| Interventions | Saredutant, Escitalopram, Placebo |
| Enrollment | 365 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Dec 29, 2006 |
| Last update posted | May 24, 2016 |
| Countries | Belgium, Canada, Finland, France, Italy, Sweden, Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: